Package Leaflet:Information for the Patient
Actos 15mg tablets
Actos 30mg tablets
Actos 45mg tablets
pioglitazone
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information:
Actos contains pioglitazone. It is an antidiabetic medicine used to treat type 2 diabetes mellitus (non-insulin-dependent) in adults, when metformin is not suitable or has not worked well enough. This type of diabetes usually occurs in adults.
Actos helps to control the level of sugar in your blood when you have type 2 diabetes. It makes your body use insulin better. Your doctor will check the effect that Actos is having on you between 3 and 6 months after you start treatment.
Actos tablets can be used on their own in patients who cannot take metformin and when diet and exercise have not been enough to control blood sugar levels, or they can be added to other treatments (such as metformin, sulphonylurea or insulin) if these have not been enough to control blood sugar levels.
Do not take Actos:
Warnings and precautions
Talk to your doctor or pharmacist before you start taking Actos (see also section 4)
If you take Actos with other diabetes medicines, you are more likely to get low blood sugar (hypoglycaemia).
You may also show a decrease in blood cell count (anaemia)
Bone fractures
There have been more bone fractures in patients, especially women, taking pioglitazone. Your doctor will take this into account when treating your diabetes.
Children and adolescents
Actos is not recommended for children and adolescents under 18 years.
Other medicines and Actos
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including those you can buy without a prescription.
You can normally keep taking other medicines while you are taking Actos tablets. However, some medicines have a greater chance of affecting your blood sugar levels:
Tell your doctor or pharmacist if you are taking any of these medicines. They will check your blood sugar levels and may need to adjust your dose of Actos.
Taking Actos with food and drink
You can take the tablets with or without food. Take them with a glass of water.
Pregnancy and breast-feeding
Tell your doctor if:
Your doctor will advise you to stop taking this medicine.
Driving and using machines
This medicine does not affect your ability to drive or use machines, but be careful if you experience visual disturbances.
Actos contains lactose monohydrate
If your doctor has told you that you have an intolerance to some sugars, contact them before taking Actos.
Follow exactly the instructions given to you by your doctor or pharmacist. If you are not sure, ask your doctor or pharmacist.
The recommended starting dose is one 15 mg or 30 mg pioglitazone tablet per day. Your doctor may increase the dose to a maximum of 45 mg once a day. Your doctor will tell you which dose to take.
If you think that the effect of Actos is too weak, talk to your doctor.
When you take Actos with other medicines used to treat diabetes (such as insulin, chlorpropamide, glibenclamida, gliclazide, tolbutamide), your doctor will tell you whether you need to take a lower dose of these medicines.
Your doctor will ask you to have regular blood tests while you are taking Actos. These tests are to check that your liver is working normally.
If you follow a special diet for diabetes, keep to it while you are taking Actos.
You should check your weight regularly. If you gain weight, talk to your doctor.
If you take more Actos than you should
If you accidentally take too many tablets, or if someone else takes your medicine, talk to your doctor or pharmacist immediately. Your blood sugar levels may become too low, but you can increase them by taking sugar. It is a good idea to carry some sugar lumps, sweets, biscuits or some fruit juice with you.
If you forget to take Actos
Take Actos every day as prescribed by your doctor. If you forget to take a dose, carry on with the next dose as usual. Do not take a double dose to make up for a forgotten dose.
If you stop taking Actos
Actos should be taken every day to have the right effect. If you stop taking Actos, your blood sugar levels may increase. Talk to your doctor before stopping treatment.
If you have any other questions about the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
In particular, patients have reported the following serious side effects:
Heart failure, which is common (may affect up to 1 in 10 people) in patients taking Actos in combination with insulin. The symptoms are unusual shortness of breath or rapid weight gain or localised swelling (oedema). If you notice any of these symptoms, especially if you are over 65 years old, talk to your doctor as soon as possible.
Uncommonly (may affect up to 1 in 100 people), bladder cancer has been reported in patients taking Actos. The signs and symptoms include blood in your urine, pain when urinating or an urgent need to urinate. If you notice any of these symptoms, talk to your doctor as soon as possible.
Patients taking Actos in combination with insulin have also commonly (may affect more than 1 in 10 people) reported localised swelling (oedema). Talk to your doctor as soon as possible if you notice this side effect.
Bone fractures: bone fractures have been reported commonly (may affect up to 1 in 10 people) in both men and women taking Actos (the frequency cannot be estimated from the available data). Talk to your doctor as soon as possible if you notice this side effect.
Blurred vision due to swelling (or fluid) at the back of the eye has also been reported in patients taking Actos (the frequency cannot be estimated from the available data). If you notice this symptom for the first time or if you already have it and it gets worse, talk to your doctor as soon as possible.
Allergic reactions have been reported with an unknown frequency (cannot be estimated from the available data) in patients treated with Actos. If you have a severe allergic reaction, including hives and swelling of the face, lips, tongue or throat that may cause difficulty in breathing or swallowing, stop taking this medicine and talk to your doctor as soon as possible.
Other side effects that have been reported by some patients taking Actos are:
common (may affect up to 1 in 10 people)
uncommon (may affect up to 1 in 100 people)
unknown frequency (cannot be estimated from the available data)
Other side effects that have been reported by some patients taking Actos with other anti-diabetic medicines are:
very common (may affect more than 1 in 10 people)
common (may affect up to 1 in 10 people)
uncommon (may affect up to 1 in 100 people)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP and on the blister after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
What Actos contains
Each Actos 15 mg tablet contains 15 mg pioglitazone (as hydrochloride).
Each Actos 30 mg tablet contains 30 mg pioglitazone (as hydrochloride).
Each Actos 45 mg tablet contains 45 mg pioglitazone (as hydrochloride).
Appearance of Actos and contents of the pack
The tablets are packaged in blister packs of 28, 56, 98 or 112 tablets. Not all pack sizes may be marketed.
Marketing authorisation holder
CHEPLAPHARM Arzneimittel GmbH
Ziegelhof 24
17489 Greifswald
Germany
Manufacturer
Takeda Ireland Limited, Bray Business Park, Kilruddery, County Wicklow, Ireland.
Lilly S.A., Avda. de la Industria 30. 28108 Alcobendas (Madrid), Spain.
CHEPLAPHARM Arzneimittel GmbH, Ziegelhof 23-24, 17489 Greifswald, Germany
Date of last revision of this leaflet: August 2023
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site http://www.ema.europa.eu
AnnexIV
SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE MARKETING AUTHORISATIONS
Scientific conclusions
Taking into account the provisions of the Pharmacovigilance Risk Assessment Committee (PRAC) report on the periodic safety update reports (PSURs) for glimepiride / pioglitazone hydrochloride, metformin / pioglitazone, pioglitazone, the scientific conclusions of the Committee for Medicinal Products for Human Use (CHMP) are as follows:
The PRAC provided updated information on important identified risks and important potential risks, as listed in the summary of safety concerns. The data submitted during the current reporting period did not provide new information that would further reduce, mitigate or characterise these risks. According to the data submitted, the risk minimisation measures of the approved product information are considered adequate for the listed safety concerns.
Given the accumulation of data since the implementation of the additional risk minimisation measures, the PRAC accepted the proposal of the PRAC to remove the additional risk minimisation measures. As a consequence, the conditions or restrictions related to the safe and effective use of the medicinal product should be updated to remove the additional risk minimisation measures. The RMP has been updated accordingly.
The CHMP agrees with the scientific conclusions of the PRAC.
Grounds for amendment of the marketing authorisations
In accordance with the scientific conclusions for glimepiride / pioglitazone hydrochloride, metformin / pioglitazone, pioglitazone, the CHMP considers that the benefit-risk balance of the medicinal product(s) containing glimepiride / pioglitazone hydrochloride, metformin / pioglitazone, pioglitazone is not affected subject to the proposed changes in the product information.
The CHMP recommends that the marketing authorisations should be amended.